SELLAS Life Sciences (SLS) Net Income Growth (1y) (2012 - 2026)
SELLAS Life Sciences (SLS) Net Income Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 63.48% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.89 Bn | 1.78 Bn | - | -140.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.35% |
| Dec 31, 2025 | -19.05% |
| Sep 30, 2025 | 1.97% |
| Jun 30, 2025 | -15.65% |
| Mar 31, 2025 | 35.73% |
| Dec 31, 2024 | 15.21% |
| Sep 30, 2024 | 21.48% |
| Jun 30, 2024 | 15.62% |
| Mar 31, 2024 | 14.37% |
| Dec 31, 2023 | 14.19% |
| Sep 30, 2023 | -30.57% |
| Jun 30, 2023 | -4.90% |
| Mar 31, 2023 | 32.40% |
| Dec 31, 2022 | 17.69% |
| Sep 30, 2022 | -2.39% |
| Jun 30, 2022 | -91.59% |
| Mar 31, 2022 | -617.91% |
| Dec 31, 2021 | -175.16% |
| Sep 30, 2021 | -54.12% |
| Jun 30, 2021 | -4.26% |